Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Expert Rev Anticancer Ther. 2022 Jan;22(1):27-38. doi: 10.1080/14737140.2022.1999809. Epub 2021 Nov 15.
Intrahepatic cholangiocarcinoma (ICC) incidence continues to rise worldwide, and overall survival remains poor. Complete surgical resection remains the only opportunity for cure in patients with ICC yet only one-third of patients present with resectable disease.
While the low incidence rate of ICC hinders accrual of patients to large, randomized control trials, larger database and long-term institutional studies provide evidence to guide surgical management of ICC. These studies demonstrate feasibility, safety, and efficacy of aggressive surgical management in appropriately selected patients with ICC. Recent advances in the management of ICC, with a focus on surgical considerations, are reviewed.
Historically, little progress has been made in the management of ICC with stagnant mortality rates and poor long-term outcomes. However, regionalization of care to centers with experienced multidisciplinary teams, advances in minimally invasive surgical techniques, discovery and development of targeted and immunotherapy agents, and combination locoregional and systemic therapies offer signs of progress in the management of ICC.
肝内胆管细胞癌 (ICC) 的发病率在全球范围内持续上升,整体生存率仍然较差。完全手术切除仍然是 ICC 患者治愈的唯一机会,但只有三分之一的患者出现可切除的疾病。
尽管 ICC 的低发病率阻碍了对大型随机对照试验的患者入组,但更大的数据库和长期机构研究提供了证据,指导 ICC 的手术管理。这些研究证明了在适当选择的 ICC 患者中采用积极的手术管理是可行、安全和有效的。本文回顾了 ICC 管理方面的最新进展,重点讨论了手术方面的考虑因素。
从历史上看,ICC 的管理几乎没有取得进展,死亡率停滞不前,长期预后不佳。然而,将护理区域化到具有丰富多学科团队经验的中心、微创外科技术的进步、靶向和免疫治疗药物的发现和开发,以及局部和全身联合治疗,为 ICC 的管理带来了一些进步的迹象。